Firmagon® is the commercial brand name of Degarelix Acetate for Injection, a subcutaneously administered gonadotropin-releasing hormone (GnRH) antagonist developed by Ferring Pharmaceuticals. It competitively blocks GnRH receptors in the pituitary gland, rapidly suppresses luteinizing hormone and follicle-stimulating hormone secretion, lowers serum testosterone levels without inducing initial testosterone surge.
Main Indications
For prostate cancer patients requiring androgen deprivation therapy.
Clinical Research
Global multicenter phase III pivotal trial confirmed degarelix achieves rapid testosterone suppression without testosterone flare compared with GnRH agonist;
Long-term follow-up cohorts demonstrated sustained castrate testosterone levels under periodic subcutaneous administration;
Dose-finding research verified reliable testosterone-lowering efficacy and local injection tolerability of the 120mg starting dose regimen;
Chinese domestic registration trials confirmed consistent therapeutic activity and manageable adverse reaction spectrum for domestic prostate cancer populations.
Common Side Effects
Common mild adverse reactions: Injection site pain, erythema, swelling, hot flushes, fatigue and weight gain;
Laboratory abnormalities: Transient mild elevation of liver enzymes;
Severe but uncommon risks: Hypersensitivity reactions, urinary tract obstruction and spinal cord compression.
Approval Status in China
Original drug Firmagon® (Degarelix Acetate for Injection) was officially approved for marketing in China in 2018, with the specification of 120mg per vial. It is currently a prescription endocrine anti-prostate cancer drug included in China’s Category B medical insurance catalogue.
Buy Firmagon (Degarelix Acetate for Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
